Loading clinical trials...
Loading clinical trials...
Phase I/II Trial of Letrozole (Femara) and Sorafenib (Nexavar) in Postmenopausal Women With Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer
Letrozole is an aromatase inhibitor that is approved in the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. Sorafenib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. This phase I/II trial is studying the side effects and best dose of sorafenib when given in combination with letrozole and to see how well they work in treating postmenopausal women with metastatic breast cancer.
Age
18 - No limit years
Sex
FEMALE
Healthy Volunteers
No
Georgetown University Hospital
Washington D.C., District of Columbia, United States
Emory University
Atlanta, Georgia, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Cooper Hospital/University Medical Center
Voorhees Township, New Jersey, United States
Start Date
August 11, 2008
Primary Completion Date
April 20, 2019
Completion Date
April 28, 2023
Last Updated
November 9, 2023
52
ACTUAL participants
Sorafenib
DRUG
Letrozole
DRUG
Lead Sponsor
Rutgers, The State University of New Jersey
Collaborators
NCT06625775
NCT06649331
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions